Asian experts surveyed in a new report fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease.
Summary:
Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services
Press Release
Asian experts fear that the last mile in malaria elimination in the region is threatened by increasing resistance to antimalarials and insecticides – new tools will be needed to defeat the disease
Another major hurdle to meeting elimination targets in South and Southeast Asia will be reaching mobile and migrant populations in remote areas
Elimination will also depend on countries in the region maintaining malaria expertise as they develop their primary healthcare services
The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
Press Release
The European & Developing Countries Clinical Trials Partnership (EDCTP) grants €10 million over five years to “WANECAM 2” a unique collaboration between antimalarial drug researchers in Africa and Europe from ten academic institutions, a pharmaceutical company, Novartis, and a not-for-profit product development partnership (PDP), Medicines for Malaria Venture.
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation. KAF156 has demonstrated the potential to treat resistant malaria and to be administered as a single dose.
The grant will also help to build and strengthen research capabilities in the four participating African countries: Burkina Faso, Gabon, Mali and Niger.
The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy
Press Release
BASEL, Switzerland, March 26, 2018 /3BL Media/ – The Novartis Foundation and Microsoft are partnering to develop an Artificial Intelligence (AI)-enabled Digital Health tool and a Leprosy Intelligent Image Atlas to aid in the early detection of leprosy. Over 200,000 people are diagnosed with leprosy every year. Brazil, India, and Indonesia account for about 80% of new cases. If untreated, patients are left with lifelong disabilities and are often stigmatized in their societies.
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Press Release
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019
Chagas disease is a potentially life-threatening neglected disease, affecting approximately six million people worldwide1,2, mostly in Latin America; up to 30% of chronically infected people develop cardiac disorders3
Chagas cardiomyopathy is the most important clinical manifestation of the disease, resulting in the majority of morbidity and mortality4
The Global Chagas Disease Coalition is a collaborative alliance, which aims to increase awareness of Chagas disease and foster synergies in controlling the disease and promoting access to diagnosis and treatment5
Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
15 000 babies are born with sickle cell disease every year in Ghana1
Press Release
Memorandum of Understanding signed between Ministry of Health, Ghana Health Service, Sickle Cell Foundation of Ghana and global medicines company Novartis
Partnership to include the establishment of treatment guidelines, newborn screening, centers of excellence and the availability of accessible treatment options in line with the global standards of care
15 000 babies are born with sickle cell disease every year in Ghana1
Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging
Press Release
Competition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands
Three finalists shared innovative uses of artificial intelligence, mobile apps and digital therapeutics to address local healthcare access challenges
Finalists will participate in a four-day “accelerator event” in March, collaborating with Sandoz to further refine their ideas, immediately ahead of final judging
Registration now open for the premier venue for shared value leaders
Blog
May 7-8, 2019
Marriott Long Wharf | Boston, Massachusetts
The era of purpose-driven business is upon us: from investors to global brands to consumers and CEOs alike, seemingly everyone is talking about the importance of purpose in driving business strategy and societal well-being. How can organizations fully deliver on the promise of purpose, moving from inspirational vision to meaningful results?
